Clinical trial close-out procedures: the close-out visit as a verification gate

At a glance

• Close-out is a workflow with three phases: reconciliation before the close-out visit (COV), the visit itself, and archiving after the site is deactivated.
• At close-out the monitor confirms two things ICH E6(R3) names: the arrangement for retaining the essential records, and final accountability of the investigational product (§3.11.4.5.2(j)).
• Participant care does not end at the last visit: the investigator ensures adequate medical care for trial-related adverse events during and after participation (ICH E6(R3) §2.7.1(c)).
• A premature or for-cause termination runs on a faster track, with prompt notice to participants, the IRB/IEC and regulators (ICH E6(R3) §2.6.1, §3.17.1) and, under a US IND, return or disposition of unused drug (21 CFR 312.59).
• Records outlive the close-out: under 21 CFR 312.62(c) the investigator keeps them for 2 years after approval for the indication, or after the investigation is discontinued and FDA is notified, and EU trial master files are archived for at least 25 years (EMA TMF guideline §6.3).

Clinical trial close-out is the set of procedures that takes a site from its last participant visit to a deactivated site with a complete, archived file. The close-out visit is the gate in the middle of that work. It verifies that investigational product is reconciled, essential records are complete and arranged for retention, and the required reports have gone out. It cannot create any of those conditions, so a COV booked before they exist turns into a list of open actions instead of a close-out. This page sets out the sequence, what the visit verifies, who reports what, and how a premature termination changes the order.

Close-out runs in three phases

Phase	What happens	Owner	Output
1. Reconciliation	Last participant visit done, queries resolved, data sets finalised, IP returns and destruction authorised	Site, data management, sponsor	A site that can be verified
2. Close-out visit	Monitor confirms IP accountability, essential records, reports and notifications, and the retention arrangement	Monitor (CRA)	Close-out monitoring report
3. Archiving	File reviewed for completeness, then archived under named custodians	Investigator / institution and sponsor	Archived TMF and investigator site file

Phase 1 is the longest and decides whether phase 2 can happen. Under ICH E6(R3), activities to finalise the data sets before analysis are confirmed and documented according to pre-specified procedures. They may include reconciling databases, correcting data errors, medical coding and addressing the impact of protocol deviations (§4.2.6(b)). Open queries at a site are part of that work, which is why they block the close-out. The clinical trial database lock guide covers the data side in detail.

Archiving has its own precondition. The EMA TMF guideline says archiving should be undertaken after the investigator or institution and the sponsor have reviewed that their filed TMF documentation is complete (EMA TMF guideline §6).

Before you book the close-out visit

Treat these as prerequisites. If one is open, the visit is early.

Prerequisite	Owner	Why it must close first
Last participant’s last visit complete, follow-up per protocol scheduled	Investigator	No new participant data or IP use after this point
Outstanding data queries resolved	Site and data management	The monitor cannot confirm source and data that are still changing
IP records current: receipt, use per participant, returns, destruction	Investigator or pharmacist	Final accountability needs complete records to check against
Sponsor authorisation for IP return or destruction	Sponsor	Disposition cannot be confirmed without it
Investigator site file self-check against the essential records list	Site	Gaps found at the visit delay the close-out

The IP row rests on a specific duty. The investigator or institution, or a pharmacist, maintains records of the product’s delivery, inventory, use by each participant, return to the sponsor and destruction or alternative disposition, including dates, quantities, batch or serial numbers, expiration dates and the code numbers assigned to product and participants (ICH E6(R3) §2.10.4). Under a US IND the investigator also keeps disposition records with dates, quantity and use by subjects (21 CFR 312.62(a)). Drug accountability in clinical trials walks through the reconciliation itself.

What the close-out visit verifies

E6(R3) lists the monitor’s site duties under one heading that runs from site selection to close-out. At close-out specifically, the monitor confirms the arrangement for the retention of the essential records and the final accountability of the investigational product, for example its return and destruction or alternative disposition (§3.11.4.5.2(j)). The other items on that list apply at the last visit as at every visit.

Verified at the COV	Grounding	What “closed” looks like
Final IP accountability	ICH E6(R3) §3.11.4.5.2(j), §2.10.4	Receipts, dispensing, returns and destruction reconcile, with dates, quantities and batch numbers
Essential records maintained	ICH E6(R3) §3.11.4.5.2(c)	The investigator site file holds what Appendix C requires for this trial
Source records and their location	ICH E6(R3) §3.11.4.5.2(f)	Source for each participant confirmed and located as the protocol requires
Adverse event reporting	ICH E6(R3) §3.11.4.5.2(e)	Adverse events reported within the periods the protocol and regulations set
Reports and notifications	ICH E6(R3) §3.11.4.5.2(i)	Reports required by the protocol and trial procedures sent and filed
Retention arrangement	ICH E6(R3) §3.11.4.5.2(j)	A named custodian, a storage location and the retention instructions on file

The visit also produces a record of its own. Site monitoring reports, including the close-out report, are listed among the essential records in Appendix C of E6(R3), and so is documentation of IP destruction or alternative disposition (ICH E6(R3) Appendix C). For what that report should contain, see the monitoring visit report as oversight evidence. The full list for the visit day lives in the clinical trial close-out checklist.

Participant care continues after the last visit

Close-out ends the trial at the site. It does not end the investigator’s duty to participants. During and following participation in a trial, the investigator or institution ensures adequate medical care is provided for any adverse events, including clinically significant laboratory values, related to the trial (ICH E6(R3) §2.7.1(c)). If the participant has a primary physician and agrees, the investigator informs that physician about the participant’s involvement in the trial (§2.7.1(d)).

Safety reporting also stays live until the last event is closed. Under a US IND, the investigator reports any serious adverse event to the sponsor immediately, whether or not it is considered drug related (21 CFR 312.64(b)). A close-out plan that has no owner for late adverse events leaves that duty unassigned.

Final reports: who sends what to whom

Close-out produces several documents, and each one comes from a different party for a different reader.

Who	Sends	To	Source
Monitor	Close-out monitoring report	Sponsor (filed in the TMF)	ICH E6(R3) §3.11.4.5.2(j), Appendix C
Investigator / institution	Summary of the trial’s outcome, and any required reports	IRB/IEC, and regulators where applicable	ICH E6(R3) §2.13
Investigator (US IND)	An adequate final report, shortly after their participation ends	Sponsor	21 CFR 312.64(c)
Sponsor	Clinical trial reports, whether the trial completed or terminated early	Regulatory authorities, as required	ICH E6(R3) §3.17.2(a)
Sponsor	Written retention requirements, and later written notice that records are no longer needed	Investigators / institutions	ICH E6(R3) §3.16.3(b)

The IRB/IEC hears about the trial both during its conduct and at its end. E6(R3) asks the investigator or sponsor to submit documented summaries of the trial status to the IRB/IEC in accordance with local regulatory requirements or upon request (§2.4.5), and asks the investigator to give the IRB/IEC a summary of the trial’s outcome upon completion (§2.13). Under a US IND, the investigator also promptly reports to the IRB all changes in the research activity and all unanticipated problems involving risk to human subjects or others (21 CFR 312.66).

None of these documents makes a site compliant. Each one attests that a specific step was done.

Premature and for-cause termination

A trial that stops early does not get the routine close-out calendar. If a trial is prematurely terminated or suspended for any reason, the investigator or institution promptly informs the participants and ensures appropriate therapy and follow-up for them (ICH E6(R3) §2.6.1). The sponsor promptly informs investigators, institutions and the regulatory authorities of the termination and the reasons, and the IRB/IEC is also informed promptly with the reasons (§3.17.1). An investigator who stops their own involvement without the sponsor’s prior agreement promptly informs the institution, the sponsor, the IRB/IEC and the regulators, with a detailed explanation (§2.6.2).

Under a US IND, two triggers set the pace. A sponsor that finds an investigator not complying with the signed agreement, the investigational plan or Part 312 promptly either secures compliance or discontinues shipments and ends that investigator’s participation, then requires the drug to be returned or disposed of under 312.59, and notifies FDA (21 CFR 312.56(b)). A sponsor that determines its drug presents an unreasonable and significant risk to subjects discontinues the affected investigations as soon as possible and no later than 5 working days after the determination, notifies FDA, all IRBs and all investigators who have ever participated, and assures disposition of all outstanding drug (21 CFR 312.56(d)).

	Routine end-of-study close-out	Premature or for-cause termination
Trigger	Planned end, last participant’s last visit	Sponsor, investigator, IRB/IEC or safety decision mid-trial
Participants	Follow-up per protocol	Prompt notice, plus appropriate therapy and follow-up (ICH E6(R3) §2.6.1)
Notifications	Outcome summary to IRB/IEC, required reports to regulators (§2.13)	Prompt notice with reasons to investigators, IRB/IEC and regulators (§3.17.1, §2.6.2, §2.6.3)
Unused IP	Reconciled and disposed of on the close-out timeline	Return of all unused supplies from each terminated investigator (21 CFR 312.59), or disposition of all outstanding stock after a safety discontinuation (21 CFR 312.56(d))
US timing	Set by the close-out plan	No later than 5 working days after a sponsor’s significant-risk determination (21 CFR 312.56(d))

A close-out visit can still follow a termination, but it comes after the safety and notification steps.

Remote close-out: what it can confirm

E6(R3) allows site monitoring to be performed on-site and/or remotely, with the sponsor deciding the extent and nature of monitoring based on identified risks (§3.11.4). Monitoring may include remote, secure, direct read-only access to source records and essential record retention systems (§3.11.4.1(c)).

That makes the document side of close-out workable at a distance when records are electronic: confirming the site file is complete, reviewing query resolution, checking reports went out. What a remote visit cannot do is count physical product or inspect a paper archive. Because the monitor still has to confirm final IP accountability and the retention arrangement (§3.11.4.5.2(j)), the deciding question is whether those two confirmations can be made through the channel chosen. If product or paper records remain on site, plan an on-site step for them. Remote monitoring in clinical trials covers the access arrangements.

Record retention after close-out

Retention runs long after the site is deactivated, and not always from the same date. Under a US IND, the investigator retains records for 2 years after a marketing application is approved for the drug for the indication investigated or, if no application is filed or it is not approved, until 2 years after the investigation is discontinued and FDA is notified (21 CFR 312.62(c)). For EU trials, the EMA TMF guideline quotes Article 58 of the Clinical Trials Regulation: the sponsor and the investigator archive the content of the clinical TMF for at least 25 years after the end of the trial (EMA TMF guideline §6.3). The two periods differ in length and in the event they count from, and neither text says how to combine them for a trial that runs under both.

ICH E6(R3) adds no number of its own. The investigator keeps essential records for the period applicable regulations require, or until the sponsor says they are no longer needed, whichever is the longest (§2.12.12), and keeps the sponsor informed of who is responsible for them during the retention period, for example when the site closes or an investigator leaves (§2.12.13). The full table of periods, triggers and archiving duties is in GCP record retention and TMF archiving.

Where close-outs stall

• The COV is booked against a calendar date, not against the prerequisites. Open queries or missing IP returns turn the visit into an action list.
• Nobody owns late adverse events once the study team moves on, though the investigator’s care duty continues after participation.
• A termination inherits the routine timeline, so participant notice and IP recovery wait for a visit that should have come after them.
• The retention custodian is “the department”. When the coordinator who knew where the boxes went leaves, the sponsor has no name on file.
• The file is archived before the completeness review, so gaps are found years later by someone who cannot fix them.

Sources

• ICH E6(R3) Good Clinical Practice, version R3
• 21 CFR Part 312, Investigational New Drug Application (current as of 4/14/2026)
• EMA Guideline on the content, management and archiving of the clinical trial master file (paper and/or electronic), EMA/INS/GCP/856758/2018